Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

Plain-language summary

This study investigates the combined use of CDK4/6 inhibition with Palbociclib and anti-VEGF targeting with Bevacizumab in solid tumors. It enrolls patients over 18 with stage III/IV disease in selected cancer types such as colorectal, lung, genitourinary, or breast cancer. The study is being conducted in Phase 1 and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Recruiting

Sponsor

Lebanese University

Intervention

SNP, Palbociclib 125mg, Bevacizumab

Start date

2/15/2023

Estimated completion

12/1/2027

Countries

Lebanon

Related genes

Locations

• Tripoli, Lebanon
• Tripoli, Lebanon

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Individuals of white ethnicity.
* Age between \> 18
* Both males and females.
* Diagnosis of selected cancer type (e.g., colorectal cancer, lung cancer, genitourinary cancers, breast cancer).
* Cancer stage III/ IV with or without metastasis or lymph node dissemination at the time of enrollment.
* Unrelated patients.

Exclusion Criteria:

* History of hematological cancer types or previous cancers, recurrent or relapse.
* Diagnosis of inflammatory bowel diseases.
* Pre-existing cardiovascular diseases or coronary artery diseases.
* Confirmed treated or untreated autoimmune diseases.
* Metabolic disorders, diabetes, or hypertension.
* Neurological diseases.
* Evidence of cardiac, renal, bone, or cerebral damage.
* Presence of more than one type of malignancies.
* Active infections or myositis.
* Familial polyposis.
* Alcohol or smoking habits.
* Body mass index (BMI) \>30.
* Significant weight loss within the last 2 years.
* History of surgeries.
* Pregnancy.
* Related patients.